{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:36:38Z","timestamp":1771961798915,"version":"3.50.1"},"reference-count":49,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To perform a Cochrane systematic review of benefit (American College of Rheumatology 50% improvement criteria; ACR50) and safety (adverse events and withdrawals) of golimumab in patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), OVID Medline, CINAHL, Embase, Science Citation Index (Web of Science), and Current Controlled Trials databases for randomized or controlled clinical trials of golimumab compared to placebo or disease-modifying antirheumatic drug in adults with RA. Two authors independently selected appropriate studies and abstracted study characteristics and safety and efficacy data and performed risk-of-bias assessment. We calculated mean differences for continuous measures, and relative risks for categorical measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Four randomized controlled trials with 1231 golimumab-treated and 483 placebo-treated patients were included. Of these, 436 were treated with golimumab at 50 mg every 4 weeks [a dosage approved by the US Food and Drug Administration (FDA)]. At an average of 4\u20136 months, compared to patients treated with placebo and methotrexate (MTX), patients treated with the FDA-approved dosage of golimumab and MTX were 2.6 times more likely to reach ACR50 (p = 0.005, 95% CI 1.3, 4.9; absolute percentage, 38% vs 15%) and 0.5 times as likely to have overall withdrawals (p = 0.005, 95% CI 0.3, 0.8; absolute percentage, 5% vs 10%). Golimumab-treated patients were significantly more likely than those taking placebo to achieve remission (22% vs 4%; p &lt; 0.00001), and to have improvement in functional ability on the Health Assessment questionnaire [0.2 points lower (p &lt; 0.00001, 95% CI 0.25, 0.15); absolute risk difference, \u221220% (95% CI \u221225% to \u221215%); relative percentage difference, \u221211% (95% CI \u221214% to \u22128.3%)]. The studies were too small and short to be powered sufficiently for safety outcomes, but no substantive statistically significant differences were noted between golimumab and placebo regarding adverse events, serious adverse events, infections, serious infections, lung infections, tuberculosis, cancer, withdrawals due to adverse events, and withdrawals due to inefficacy and deaths.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>At the approved dosage, in patients with active RA taking background MTX, golimumab is significantly more beneficial than placebo. The short-term safety profile is reasonable. Longterm surveillance studies are needed for safety assessment.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.091466","type":"journal-article","created":{"date-parts":[[2010,5,2]],"date-time":"2010-05-02T00:24:31Z","timestamp":1272759871000},"page":"1096-1104","source":"Crossref","is-referenced-by-count":29,"title":["Golimumab for Rheumatoid Arthritis: A Systematic Review"],"prefix":"10.3899","volume":"37","author":[{"given":"JASVINDER A.","family":"SINGH","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHAHRZAD","family":"NOORBALOOCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GURKIRPAL","family":"SINGH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2010,5,1]]},"reference":[{"key":"2018112909231436000_37.6.1096.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06075-5"},{"key":"2018112909231436000_37.6.1096.2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500327727"},{"issue":"2 Suppl 1","key":"2018112909231436000_37.6.1096.3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"2018112909231436000_37.6.1096.4","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510018633"},{"key":"2018112909231436000_37.6.1096.5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/BOR.0b013e3280126b66","article-title":"Work disability in rheumatic diseases","volume":"19","author":"Yelin","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"2018112909231436000_37.6.1096.6","first-page":"12","article-title":"The pathogenesis of rheumatoid arthritis","volume":"64","author":"Weissmann","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2018112909231436000_37.6.1096.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"2018112909231436000_37.6.1096.8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36389"},{"key":"2018112909231436000_37.6.1096.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.05.011"},{"key":"2018112909231436000_37.6.1096.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct055183"},{"key":"2018112909231436000_37.6.1096.11","doi-asserted-by":"crossref","unstructured":"Blumenauer B Cranney A Burls A Coyle D Hochberg M Tugwell P Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD004525.","DOI":"10.1002\/14651858.CD004525"},{"key":"2018112909231436000_37.6.1096.12","doi-asserted-by":"crossref","unstructured":"Blumenauer B Judd M Wells G Burls A Cranney A Hochberg M Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2002:CD003785.","DOI":"10.1002\/14651858.CD003785"},{"key":"2018112909231436000_37.6.1096.13","unstructured":"Navarro-Sarabia F Ariza-Ariza R Hernandez-Cruz B Villanueva I . [Adalimumab for treating rheumatoid arthritis]. Cochrane Database Syst Rev 2005:CD005113."},{"key":"2018112909231436000_37.6.1096.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090074"},{"key":"2018112909231436000_37.6.1096.15","doi-asserted-by":"crossref","unstructured":"Maxwell L Singh JA . Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009:CD007277.","DOI":"10.1002\/14651858.CD007277.pub2"},{"key":"2018112909231436000_37.6.1096.16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.bor.0000265447.48722.04","article-title":"The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence","volume":"19","author":"Siddiqui","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"2018112909231436000_37.6.1096.17","unstructured":"US Food and Drug Administration. Simponi\u00c2\u00ae (golimumab) physician packet insert: highlights of prescribing information, 2009. [Internet. Accessed March 15, 2010. ] Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125289s000lbl.pdf"},{"key":"2018112909231436000_37.6.1096.18","unstructured":"US Food and Drug Administration. Simponi\u00c2\u00ae (golimumab) summary review. FDA Center for Drug Evaluation and Research, 2009. [Internet. Accessed Sept 20, 2009.] Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125289s000_SumR.pdf"},{"key":"2018112909231436000_37.6.1096.19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2018112909231436000_37.6.1096.20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2018112909231436000_37.6.1096.21","first-page":"2146","article-title":"An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis","volume":"33","author":"Pincus","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909231436000_37.6.1096.22","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient\u00e2\u0080\u0099s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"2018112909231436000_37.6.1096.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048975"},{"key":"2018112909231436000_37.6.1096.24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2018112909231436000_37.6.1096.25","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"2018112909231436000_37.6.1096.26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl 39","key":"2018112909231436000_37.6.1096.27","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909231436000_37.6.1096.28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2018112909231436000_37.6.1096.29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiol Diagn"},{"key":"2018112909231436000_37.6.1096.30","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis Rheum"},{"key":"2018112909231436000_37.6.1096.31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"van der Heijde","year":"1989","journal-title":"Lancet"},{"key":"2018112909231436000_37.6.1096.32","doi-asserted-by":"crossref","unstructured":"Higgins JP Altman DG . Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions, version 5.0.0 (updated February 2008). In: www.cochrane-handbook.org: The Cochrane Collaboration; 2008.","DOI":"10.1002\/9780470712184"},{"key":"2018112909231436000_37.6.1096.33","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-4-38"},{"key":"2018112909231436000_37.6.1096.34","doi-asserted-by":"crossref","unstructured":"Deeks J Higgins J Altman D . Analysing data and undertaking meta-analyses, Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). In: www.cochrane-handbook.org: The Cochrane Collaboration; 2008.","DOI":"10.1002\/9780470712184.ch9"},{"key":"2018112909231436000_37.6.1096.35","unstructured":"Cates C . Dr. Chris Cates\u00e2\u0080\u0099 EBM Web Site. Visual Rx Version 3. [Internet. Accessed Feb 13, 2009.] Available from: http:\/\/www.nntonline.net\/visualrx\/"},{"key":"2018112909231436000_37.6.1096.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.099010"},{"key":"2018112909231436000_37.6.1096.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.23383"},{"key":"2018112909231436000_37.6.1096.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"2018112909231436000_37.6.1096.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"2018112909231436000_37.6.1096.40","doi-asserted-by":"crossref","unstructured":"Singh JA Noorbaloochi S Singh G . Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;CD008341.","DOI":"10.1002\/14651858.CD008341"},{"key":"2018112909231436000_37.6.1096.41","doi-asserted-by":"crossref","unstructured":"Lopez-Olivo M Amezaga M McGahan L Suarez-Almazor M . Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2008;CD007356.","DOI":"10.1002\/14651858.CD007356"},{"key":"2018112909231436000_37.6.1096.42","doi-asserted-by":"publisher","DOI":"10.1186\/ar1881"},{"key":"2018112909231436000_37.6.1096.43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken034"},{"key":"2018112909231436000_37.6.1096.44","doi-asserted-by":"crossref","unstructured":"Blumenauer B Judd M Cranney A Burls A Coyle D Hochberg M Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD004525.","DOI":"10.1002\/14651858.CD004525"},{"key":"2018112909231436000_37.6.1096.45","doi-asserted-by":"crossref","unstructured":"Lopez-Olivo M Amezaga M McGahan L Suarez-Almazor M . Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev 2008:CD007356.","DOI":"10.1002\/14651858.CD007356"},{"key":"2018112909231436000_37.6.1096.46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60792-3"},{"key":"2018112909231436000_37.6.1096.47","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2982"},{"key":"2018112909231436000_37.6.1096.48","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200923020-00005"},{"key":"2018112909231436000_37.6.1096.49","first-page":"393","article-title":"Golimumab, a fully human monoclonal antibody against TNF alpha","volume":"10","author":"Hutas","year":"2008","journal-title":"Curr Opin Mol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.091466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T10:30:46Z","timestamp":1711449046000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.091466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,1]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,1]]},"published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.3899\/jrheum.091466"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.091466","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,1]]}}}